Recurrent 11q24.3 Gain Contributes to the Pathogenesis of Diffuse Large B Cell Lymphoma (DLBCL) by Deregulating ETS1 and FLI1
Paola Bonetti(Center for Pediatric Endocrinology Zurich), Francesco Bertoni(Ente Ospedaliero Cantonale), Maurilio Ponzoni(San Raffaele University of Rome), Afua A. Mensah(Institute of Oncology Research), Monica Testoni(Institute of Oncology Research), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Timothy C. Greiner(University of Nebraska Medical Center), Miguel Á. Piris(Hospital Universitario Fundación Jiménez Díaz), Marta Scandurra(Institute of Oncology Research), Ivo Kwee(Dalle Molle Institute for Artificial Intelligence Research), Emanuele Zucca(Università della Svizzera italiana), Roberto Piva(University of Turin), Maria Grazia Tibiletti(University of Insubria), Wing C. Chan(Ontario Institute for Cancer Research)
Cited by 0
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k